Literature DB >> 34921027

Relationship between Antibody Levels and SARS-Cov-2 Reinfection.

Mehmet Sami Islamoglu1, Mahir Cengiz2, Betul Borku Uysal2, Hande Ikitimur3, Zeynep Ozdemir4, Ahsen Karamehmetoglu4, Ayşe Ezgi Akbulut4, Ayşe Nur Bakdur4, Azize Ozdemir4, Habibe Kayıkcıoglu4, Hatice Ozdemir4, Rumeysa Uces4, Sema Ersoy4, Serap Yavuzer2.   

Abstract

OBJECTIVE: In this period when mutant strains are increasing all over the world, studies on how much humoral immunity will protect against the Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) are quite limited. The aim of our study is to investigate the positivity and antibody levels of the COVID-19 reverse transcription polymerase chain reaction (RT-PCR) test, the frequency of SARS-CoV-2 re-infection, and the protective antibody level against re-infection.
METHODS: Patients who were positive for COVID-19 IgG antibody between 1 July and 31 August were included in our study. The COVID-19 RT-PCR test positivity, age, gender and comorbidities of these patients were recorded before this date. The COVID-19 RT-PCR test positivity of these patients was followed from the National COVID-19 Database between September 1, 2020 and February 28, 2021.
RESULTS: 1665 patients (female: male 683: 982, mean age 40.6±13.4 years). Among all patients, 14 patients had reinfection and the frequency of reinfection was 0.8%. It was observed that the frequency of reinfection was more frequent in patients with PCR negative (p<0.001). The IgG cut-off value causing reinfection was found to be 11.9 (AUC: 0.844, 79.2% sensitivity, 78.6% specificity) (p<0.001).
CONCLUSION: Humoral antibodies against SARS-CoV-2 were protective against COVID-19 reinfection, 0.8% of the patients had reinfection and the resultant reinfection was mostly seen in PCR negative patients who were asymptomatic.
© 2021 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  COVID-19; COVID-19 reinfection; Immunity; SARS-CoV-2 antibody

Mesh:

Substances:

Year:  2021        PMID: 34921027

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  1 in total

1.  Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine.

Authors:  Livnat Brill; Ariel Rechtman; Alla Shifrin; Ayal Rozenberg; Svetlana Afanasiev; Omri Zveik; Nitzan Haham; Neta Levin; Adi Vaknin-Dembinsky
Journal:  Mult Scler Relat Disord       Date:  2022-05-10       Impact factor: 4.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.